"FDA's approval of IMAAVY TM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and CEO, MDA. "With ...

“FDA’s approval of IMAAVYTM (nipocalimab-aahu) is an important step in expanding treatment options for people living with myasthenia gravis,” said Donald S. Wood, PhD, President and ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

As the Antisemitism Awareness Act heads to a Senate committee for a crucial vote, 10 progressive Jewish organizations have signed a letter opposing the legislation for representing an endorsement ...

Antozzi C, Vu T, Ramchandren S, et al. Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: Vivacity-MG3 open-label extension phase results. Neurology. 2025;104(7 suppl 1 ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Imaavy plus standard of care led to improvements at ...

The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of ...

Democratic Congressmembers Pramila Jayapal and Debbie Dingell joined Vermont independent Senator Bernie Sanders on Tuesday in reintroducing the Medicare for All Act, which would provide universal ...

The FDA has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for the treatment of treatment of generalized myasthenia gravis (gMG). Following FDA Priority Review designation, this approval ...

On April 30, 2025, the FDA approved nipocalimab-aahu (Imaavy; Johnson & Johnson), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gMG) in adult and ...